Phage display has identified the dodecapeptide YHWYGYTPQNVI (GE11) as a ligand that binds to the epidermal growth factor receptor (EGFR) but does not activate the receptor. Here, we compare the EGFR binding affinities of GE11, EGF, and their polyethyleneimine-polyethyleneglycol (PEI-PEG) conjugates. We found that although GE11 by itself does not exhibit measurable affinity to the EGFR, tethering it to PEI-PEG increases its affinity markedly, and complex formation with polyinosine/cytosine (polyIC) further enhances the affinity to the submicromolar range. PolyIC/PPGE11 has a similar strong antitumor effect against EGFR overexpressing tumors in vitro and in vivo, as polyIC/polyethyleneimine-polyetheleneglycol-EGF (polyIC/PP-EGF). Absence of EGFR activation, as previously shown by us and easier production of GE11 and GE11 conjugates, confer polyIC/PPGE11 a significant advantage over similar EGF-based polyplexes as a potential therapy of EGFR overexpressing tumors.
Phage display has identified the dodecapeptide YHWYGYTPQNVI (n class="Chemical">GE11) as a liganpan>d that binds to the pan> class="Gene">epidermal growth factor receptor (EGFR) but does not activate the receptor. Here, we compare the EGFR binding affinities of GE11, EGF, and their polyethyleneimine-polyethyleneglycol (PEI-PEG) conjugates. We found that although GE11 by itself does not exhibit measurable affinity to the EGFR, tethering it to PEI-PEG increases its affinity markedly, and complex formation with polyinosine/cytosine (polyIC) further enhances the affinity to the submicromolar range. PolyIC/PPGE11 has a similar strong antitumor effect against EGFR overexpressing tumors in vitro and in vivo, as polyIC/polyethyleneimine-polyetheleneglycol-EGF (polyIC/PP-EGF). Absence of EGFR activation, as previously shown by us and easier production of GE11 and GE11 conjugates, confer polyIC/PPGE11 a significant advantage over similar EGF-based polyplexes as a potential therapy of EGFR overexpressing tumors.
Authors: Tie Fu Liu; Kimberley A Cohen; Jason G Ramage; Mark C Willingham; Andrew M Thorburn; Arthur E Frankel Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: H S Huang; M Nagane; C K Klingbeil; H Lin; R Nishikawa; X D Ji; C M Huang; G N Gill; H S Wiley; W K Cavenee Journal: J Biol Chem Date: 1997-01-31 Impact factor: 5.157
Authors: Markus F Wolschek; Christiane Thallinger; Malgorzata Kursa; Vanessa Rössler; Matthew Allen; Cornelia Lichtenberger; Ralf Kircheis; Trevor Lucas; Martin Willheim; Walter Reinisch; Alfred Gangl; Ernst Wagner; Burkhard Jansen Journal: Hepatology Date: 2002-11 Impact factor: 17.425
Authors: Paul L Chariou; Karin L Lee; Amy M Wen; Neetu M Gulati; Phoebe L Stewart; Nicole F Steinmetz Journal: Bioconjug Chem Date: 2015-02-05 Impact factor: 4.774
Authors: Madeline M Bashant; Saige M Mitchell; Lucy R Hart; Charlotta G Lebedenko; Ipsita A Banerjee Journal: J Mol Model Date: 2021-12-28 Impact factor: 1.810